Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study https://t.co/XVXgEoufCw Nice data another p19 IL23 inhb - safety continues to impress